DexCom, Inc. (DXCM) EV/EBIT Ratio: 28.92x
Is DexCom, Inc.’s EV/EBIT ratio high or low?
DexCom, Inc.'s EV/EBIT ratio of 28.92x is 72% below its 5-year average of 101.86x, near the low end of its 5-year range (22.28x–201.45x).
As of Friday, June 12, 2026. 25.13% below its 12-month average of 38.63x.
DXCM EV/EBIT Ratio Chart
DXCM Average EV/EBIT Ratio Chart
DXCM Current vs Average EV/EBIT Ratio Chart
DXCM EV/EBIT Ratio Metrics
EV/EBIT RATIO
28.92x
EV/EBIT RATIO AVG TTM
38.63x
EV/EBIT RATIO AVG 3Y
65.25x
EV/EBIT RATIO AVG 5Y
101.86x
EV/EBIT RATIO AVG 10Y
112.79x
EV/EBIT RATIO AVG 15Y
112.79x
EV/EBIT RATIO AVG 20Y
112.79x
CURRENT VS TTM AVG
-25.13%
CURRENT VS 3Y AVG
-55.68%
CURRENT VS 5Y AVG
-71.61%
CURRENT VS 10Y AVG
-74.36%
CURRENT VS 15Y AVG
-74.36%
CURRENT VS 20Y AVG
-74.36%
DXCM Competitors' EV/EBIT Ratio
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DexCom, Inc. (DXCM) | $29.04B | 28.92x | 38.63x | 65.25x | 101.86x |
| Biogen Inc. (BIIB) | $29.52B | 21.30x | 13.30x | 14.80x | 15.73x |
| IQVIA Holdings Inc. (IQV) | $30.22B | 13.39x | 20.38x | 24.02x | 30.00x |
| Centene Corporation (CNC) | $31.37B | N/A | 10.37x | 16.91x | 20.65x |
| Medline Inc. (MDLN) | $31.40B | 19.98x | 21.21x | 21.21x | 21.21x |
| Veeva Systems Inc. (VEEV) | $26.31B | 26.56x | 45.54x | 60.66x | 66.33x |
| Zoetis Inc. (ZTS) | $34.13B | 11.67x | 17.86x | 24.01x | 27.37x |
| Waters Corporation (WAT) | $23.21B | 54.26x | 27.55x | 26.51x | 26.24x |
| United Therapeutics Corporation (UTHR) | $23.15B | 17.17x | 13.73x | 11.86x | 13.36x |
| Mettler-Toledo International Inc. (MTD) | $23.06B | 22.11x | 26.08x | 26.29x | 29.24x |
DexCom, Inc. EV/EBIT Ratio Formula & Definition
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. EV/EBIT Ratio FAQ
- What is the EV/EBIT ratio for DexCom, Inc. (DXCM)?
- The EV/EBIT ratio for DXCM stock is 28.92x.
- Is DexCom, Inc.'s EV/EBIT ratio high or low?
- DexCom, Inc.'s EV/EBIT ratio of 28.92x is 72% below its 5-year average of 101.86x, near the low end of its 5-year range (22.28x–201.45x).
- What is the TTM average EV/EBIT ratio for DexCom, Inc. (DXCM)?
- The TTM average EV/EBIT ratio for DXCM stock is 38.63x.
- What is the 3Y average EV/EBIT ratio for DexCom, Inc. (DXCM)?
- The 3Y average EV/EBIT ratio for DXCM stock is 65.25x.
- What is the 5Y average EV/EBIT ratio for DexCom, Inc. (DXCM)?
- The 5Y average EV/EBIT ratio for DXCM stock is 101.86x.
- What is the 10Y average EV/EBIT ratio for DexCom, Inc. (DXCM)?
- The 10Y average EV/EBIT ratio for DXCM stock is 112.79x.
- What is the 15Y average EV/EBIT ratio for DexCom, Inc. (DXCM)?
- The 15Y average EV/EBIT ratio for DXCM stock is 112.79x.
- What is the 20Y average EV/EBIT ratio for DexCom, Inc. (DXCM)?
- The 20Y average EV/EBIT ratio for DXCM stock is 112.79x.
DexCom, Inc. EV/EBIT Ratio History
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-06-11 | 28.92x |
| 2026-06-10 | 28.74x |
| 2026-06-09 | 30.04x |
| 2026-06-08 | 29.44x |
| 2026-06-05 | 28.01x |
| 2026-06-04 | 27.91x |
| 2026-06-03 | 27.97x |
| 2026-06-02 | 28.23x |
| 2026-06-01 | 28.77x |
| 2026-05-29 | 28.34x |
| 2026-05-28 | 27.81x |
| 2026-05-27 | 27.02x |
| 2026-05-26 | 27.69x |
| 2026-05-22 | 27.72x |
| 2026-05-21 | 27.64x |
| 2026-05-20 | 27.47x |
| 2026-05-19 | 25.76x |
| 2026-05-18 | 25.05x |
| 2026-05-15 | 23.73x |
| 2026-05-14 | 22.28x |
| 2026-05-13 | 22.57x |
| 2026-05-12 | 23.54x |
| 2026-05-11 | 22.86x |
| 2026-05-08 | 23.34x |
| 2026-05-07 | 23.46x |
| 2026-05-06 | 23.25x |
| 2026-05-05 | 22.91x |
| 2026-05-04 | 23.13x |
| 2026-05-01 | 23.62x |
| 2026-04-30 | 22.94x |
| 2026-04-29 | 25.70x |
| 2026-04-28 | 26.47x |
| 2026-04-27 | 27.38x |
| 2026-04-24 | 27.45x |
| 2026-04-23 | 27.95x |
| 2026-04-22 | 28.26x |
| 2026-04-21 | 27.90x |
| 2026-04-20 | 28.79x |
| 2026-04-17 | 28.51x |
| 2026-04-16 | 27.30x |
| 2026-04-15 | 27.44x |
| 2026-04-14 | 28.06x |
| 2026-04-13 | 28.13x |
| 2026-04-10 | 28.53x |
| 2026-04-09 | 29.25x |
| 2026-04-08 | 29.30x |
| 2026-04-07 | 28.13x |
| 2026-04-06 | 28.17x |
| 2026-04-02 | 27.74x |
| 2026-04-01 | 27.80x |
| 2026-03-31 | 27.99x |
| 2026-03-30 | 27.60x |
| 2026-03-27 | 27.75x |
| 2026-03-26 | 29.43x |
| 2026-03-25 | 29.76x |
| 2026-03-24 | 29.65x |
| 2026-03-23 | 29.37x |
| 2026-03-20 | 29.81x |
| 2026-03-19 | 29.95x |
| 2026-03-18 | 30.12x |
| 2026-03-17 | 29.97x |
| 2026-03-16 | 29.54x |
| 2026-03-13 | 28.62x |
| 2026-03-12 | 29.07x |
| 2026-03-11 | 29.53x |
| 2026-03-10 | 30.17x |
| 2026-03-09 | 30.59x |
| 2026-03-06 | 30.31x |
| 2026-03-05 | 31.44x |
| 2026-03-04 | 32.41x |
| 2026-03-03 | 32.49x |
| 2026-03-02 | 32.80x |
| 2026-02-27 | 32.64x |
| 2026-02-26 | 33.06x |
| 2026-02-25 | 32.52x |
| 2026-02-24 | 32.49x |
| 2026-02-23 | 32.57x |
| 2026-02-20 | 32.49x |
| 2026-02-19 | 32.13x |
| 2026-02-18 | 32.37x |
| 2026-02-17 | 31.33x |
| 2026-02-13 | 31.15x |
| 2026-02-12 | 28.99x |
| 2026-02-11 | 36.65x |
| 2026-02-10 | 36.66x |
| 2026-02-09 | 37.70x |
| 2026-02-06 | 37.61x |
| 2026-02-05 | 37.56x |
| 2026-02-04 | 38.05x |
| 2026-02-03 | 38.47x |
| 2026-02-02 | 38.95x |
| 2026-01-30 | 39.21x |
| 2026-01-29 | 39.72x |
| 2026-01-28 | 39.38x |
| 2026-01-27 | 39.54x |
| 2026-01-26 | 39.37x |
| 2026-01-23 | 39.12x |
| 2026-01-22 | 39.67x |
| 2026-01-21 | 38.73x |
| 2026-01-20 | 38.00x |
| 2026-01-16 | 37.38x |
| 2026-01-15 | 37.22x |
| 2026-01-14 | 37.46x |
| 2026-01-13 | 37.75x |
| 2026-01-12 | 38.13x |
| 2026-01-09 | 36.26x |
| 2026-01-08 | 36.80x |
| 2026-01-07 | 37.67x |
| 2026-01-06 | 37.56x |
| 2026-01-05 | 36.39x |
| 2026-01-02 | 35.81x |
| 2025-12-31 | 35.72x |
| 2025-12-30 | 36.08x |
| 2025-12-29 | 36.30x |
| 2025-12-26 | 36.35x |
| 2025-12-24 | 36.27x |
| 2025-12-23 | 35.98x |
| 2025-12-22 | 36.27x |
| 2025-12-19 | 35.56x |
| 2025-12-18 | 35.48x |
| 2025-12-17 | 35.39x |
| 2025-12-16 | 35.72x |
| 2025-12-15 | 35.38x |
| 2025-12-12 | 36.03x |
| 2025-12-11 | 37.07x |
| 2025-12-10 | 36.34x |
| 2025-12-09 | 35.70x |
| 2025-12-08 | 35.33x |
| 2025-12-05 | 35.26x |
| 2025-12-04 | 35.13x |
| 2025-12-03 | 34.92x |
| 2025-12-02 | 34.71x |
| 2025-12-01 | 34.23x |
| 2025-11-28 | 34.20x |
| 2025-11-26 | 33.71x |
| 2025-11-25 | 33.27x |
| 2025-11-24 | 33.54x |
| 2025-11-21 | 32.50x |
| 2025-11-20 | 31.55x |
| 2025-11-19 | 32.24x |
| 2025-11-18 | 32.47x |
| 2025-11-17 | 31.59x |
| 2025-11-14 | 31.37x |
| 2025-11-13 | 32.24x |
| 2025-11-12 | 32.18x |
| 2025-11-11 | 31.40x |
| 2025-11-10 | 29.68x |
| 2025-11-07 | 29.76x |
| 2025-11-06 | 31.35x |
| 2025-11-05 | 32.01x |
| 2025-11-04 | 33.00x |
| 2025-11-03 | 32.61x |
| 2025-10-31 | 31.45x |
| 2025-10-30 | 36.68x |
| 2025-10-29 | 42.57x |
| 2025-10-28 | 43.19x |
| 2025-10-27 | 44.02x |
| 2025-10-24 | 43.84x |
| 2025-10-23 | 44.28x |
| 2025-10-22 | 44.06x |
| 2025-10-21 | 43.50x |
| 2025-10-20 | 42.71x |
| 2025-10-17 | 41.63x |
| 2025-10-16 | 41.47x |
| 2025-10-15 | 40.92x |
| 2025-10-14 | 41.40x |
| 2025-10-13 | 40.80x |
| 2025-10-10 | 40.75x |
| 2025-10-09 | 42.51x |
| 2025-10-08 | 42.33x |
| 2025-10-07 | 41.29x |
| 2025-10-06 | 41.48x |
| 2025-10-03 | 41.89x |
| 2025-10-02 | 41.53x |
| 2025-10-01 | 41.32x |
| 2025-09-30 | 42.04x |
| 2025-09-29 | 41.54x |
| 2025-09-26 | 41.92x |
| 2025-09-25 | 42.64x |
| 2025-09-24 | 42.16x |
| 2025-09-23 | 42.58x |
| 2025-09-22 | 43.36x |
| 2025-09-19 | 42.13x |
| 2025-09-18 | 47.08x |
| 2025-09-17 | 47.47x |
| 2025-09-16 | 47.54x |
| 2025-09-15 | 46.96x |
| 2025-09-12 | 47.34x |
| 2025-09-11 | 47.21x |
| 2025-09-10 | 47.21x |
| 2025-09-09 | 48.64x |
| 2025-09-08 | 48.40x |
| 2025-09-05 | 49.89x |
| 2025-09-04 | 50.04x |
| 2025-09-03 | 48.95x |
| 2025-09-02 | 46.20x |
| 2025-08-29 | 46.82x |
| 2025-08-28 | 46.66x |
| 2025-08-27 | 47.44x |
| 2025-08-26 | 47.28x |
| 2025-08-25 | 47.19x |
| 2025-08-22 | 50.93x |
| 2025-08-21 | 49.96x |
| 2025-08-20 | 50.58x |
| 2025-08-19 | 50.12x |
| 2025-08-18 | 50.07x |
| 2025-08-15 | 50.15x |
| 2025-08-14 | 49.56x |
| 2025-08-13 | 49.56x |
| 2025-08-12 | 49.69x |
| 2025-08-11 | 48.31x |
| 2025-08-08 | 48.91x |
| 2025-08-07 | 47.45x |
| 2025-08-06 | 47.45x |
| 2025-08-05 | 46.89x |
| 2025-08-04 | 47.36x |
| 2025-08-01 | 49.16x |
| 2025-07-31 | 50.04x |
| 2025-07-30 | 54.97x |
| 2025-07-29 | 60.21x |
| 2025-07-28 | 60.33x |
| 2025-07-25 | 59.98x |
| 2025-07-24 | 58.53x |
| 2025-07-23 | 58.33x |
| 2025-07-22 | 57.48x |
| 2025-07-21 | 56.78x |
| 2025-07-18 | 56.69x |
| 2025-07-17 | 56.83x |
| 2025-07-16 | 56.85x |
| 2025-07-15 | 57.27x |
| 2025-07-14 | 57.62x |
| 2025-07-11 | 56.36x |
| 2025-07-10 | 57.70x |
| 2025-07-09 | 57.32x |
| 2025-07-08 | 56.61x |
| 2025-07-07 | 56.08x |
| 2025-07-03 | 56.07x |
| 2025-07-02 | 56.49x |
| 2025-07-01 | 56.49x |
| 2025-06-30 | 58.88x |
| 2025-06-27 | 58.26x |
| 2025-06-26 | 57.43x |
| 2025-06-25 | 57.20x |
| 2025-06-24 | 59.06x |
| 2025-06-23 | 54.08x |
| 2025-06-20 | 54.19x |
| 2025-06-18 | 54.84x |
| 2025-06-17 | 55.37x |
| 2025-06-16 | 56.12x |
| 2025-06-13 | 55.47x |
| 2025-06-12 | 56.02x |
| 2025-06-11 | 56.11x |
| 2025-06-10 | 57.29x |
| 2025-06-09 | 57.85x |
| 2025-06-06 | 58.48x |
| 2025-06-05 | 57.88x |
| 2025-06-04 | 57.80x |
| 2025-06-03 | 58.56x |
| 2025-06-02 | 57.74x |
| 2025-05-30 | 57.92x |
Showing the most recent 260 of 1,590 data points. The chart above shows the full history.
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach